Article Text

Download PDFPDF
Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens
  1. Andreas Plettenberg1,
  2. Dirk Albrecht1,
  3. Thore Lorenzen1,
  4. Volker Paech1,
  5. Heiko Petersen2,
  6. Thomas Fenner2,
  7. Thomas Meyer3,
  8. Rüdiger Arndt3,
  9. Kurt Hertogs4,
  10. Rudi Pauwels5,
  11. Thomas Weitzel1,
  12. Albrecht Stoehr1
  1. 1General Hospital St Georg, Hamburg, Germany
  2. 2Labor Fenner & Partner, Hamburg, Germany
  3. 3Labor Keeser/Arndt & Partner, Hamburg, Germany
  4. 4Virco NV Mechelen, Belgium
  5. 5Tibotec NV, Mechelen, Belgium
  1. Andreas Plettenberg, MD, General Hospital St Georg, Infectious Diseases Outpatient Department, Haus Z, Lohmuehlenstrasse 5, D-20099 Hamburg, Germany plettenberg{at}


Objective: To assess HIV-1 isolate based resistance profiles from extensively pretreated patients and effects of a resistance guided switch of antiretroviral therapy.

Methods: In a prospective study phenotypic and genotypic resistance analyses were performed on HIV infected individuals with failure of the current therapy and history of at least three antiretroviral regimens. Antiretroviral therapy was changed according to the results. Viral load and CD4 lymphocyte counts were measured at baseline, after 10 (SD 2), and 24 (2) weeks.

Results: All patients (n=52) failed their actual regimen. Currently versus ever previously taking the specific drug, resistance associated mutations and phenotypic resistance to AZT and 3TC were found in over 80% of individuals; resistance to DDI and D4T was detected in less than 10% of cases. A resistance guided switch of therapy was followed by a median decrease of viral load of 0.5 log10 units after 24 weeks. Individuals resistant to two or more drugs compared with patients with resistance to less than two drugs of ongoing treatment, were switched to a regimen containing DDI, D4T, and a PI or NNRTI. After 10 (SD 2) weeks viral load decrease was pronounced in patients with resistance to at least two drugs in the previous regimen.

Conclusions: Among different RTI, the profile of clinically relevant resistance indicates pronounced differences when looking at separate drugs. Regarding virological response, in the context of available drugs, resistance tested with currently used methods is of limited value in extensively pretreated patients and seems to have its value primarily in first or second switch of therapy.

  • HIV drug resistance
  • antiretroviral therapy
  • HIV diagnostic tests

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.